Oslo 7 May 2021 - Navamedic ASA ("Navamedic", OSE: NAVA) announces it has signed
an agreement with Icepharma for distribution of the antibiotics products to the
Icelandic market.

As announced on 4 August 2020, Navamedic completed the acquisition of marketing
authorisations in the Nordics for a portfolio of antibiotics products. The
antibiotics in the portfolio, now fully onboarded on Navamedic's platform, are
designed to be given intravenously to patients and are in regular use in
hospitals in all the Nordic countries.

In accordance with the plan to roll out antibiotics in the Nordic region,
Navamedic has signed an agreement with Icepharma for distribution of the
antibiotics products to the Icelandic market.

"The addition of the antibiotics portfolio marked an important milestone for
Navamedic and our expanding hospital and prescription drug offering. We are
pleased to welcome Icepharma to join us in securing steady supply of these
important products to Nordic hospitals," says Kathrine Gamborg Andreassen, CEO
of Navamedic.

The antibiotics in the portfolio are designed to be given intravenously to
patients and are currently in regular use in hospitals in all the Nordic
countries with an annual turnover of approximately NOK 25 million. This
portfolio will strengthen NavamedicŽs hospital offering with an important
product range. This is an important step in NavamedicŽs growth strategy.

Navamedic has recruited Janne Folmoe to the company's Specialty Pharma
commercial team. Folmoe comes with extensive experience from the ACS Dobfar
portfolio with focus on tender management, and previous commercial positions in
the pharma industry in companies such as Bayer and Mylan. Folmoe will play a key
role in the commercial operation with regards to the antibiotics portfolio.

For more information, please contact:
Kathrine Gamborg Andreassen, CEO of Navamedic ASA
kathrine@navamedic.com

Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic ASA
+46 70 257 99 71
alexander.lidmejer@navamedic.com

About Navamedic

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com